These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2574781)

  • 1. Clinical trials with oral iron chelator L1.
    Kontoghiorghes GJ; Hoffbrand AV
    Lancet; 1989 Dec 23-30; 2(8678-8679):1516-7. PubMed ID: 2574781
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral deferiprone--controversies on its efficacy and safety.
    Choudhry VP
    Indian J Pediatr; 1998; 65(6):825-8. PubMed ID: 10773946
    [No Abstract]   [Full Text] [Related]  

  • 3. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).
    Rombos Y; Tzanetea R; Konstantopoulos K; Simitzis S; Zervas C; Kyriaki P; Kavouklis M; Aessopos A; Sakellaropoulos N; Karagiorga M; Kalotychou V; Loukopoulos D
    Haematologica; 2000 Feb; 85(2):115-7. PubMed ID: 10681716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferiprone for thalassaemia.
    Pippard MJ; Weatherall DJ
    Lancet; 2000 Oct; 356(9239):1444-5. PubMed ID: 11052617
    [No Abstract]   [Full Text] [Related]  

  • 5. Toxicity of oral iron chelator L1.
    Bichile SK; Mehta PJ; Parekh SJ
    J Assoc Physicians India; 1993 Jun; 41(6):323-4. PubMed ID: 8005960
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety of oral iron chelator L1.
    Kontoghiorghes GJ; Nasseri-Sina P; Goddard JG; Barr JM; Nortey P; Sheppard LN
    Lancet; 1989 Aug; 2(8660):457-8. PubMed ID: 2569645
    [No Abstract]   [Full Text] [Related]  

  • 7. The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1).
    Berdoukas V; Bohane T; Eagle C; Lindeman R; DeSilva K; Tobias V; Painter D; Fraser I
    Transfus Sci; 2000 Dec; 23(3):239-40. PubMed ID: 11099900
    [No Abstract]   [Full Text] [Related]  

  • 8. Future of oral iron chelator deferiprone. (L1) ICOC committee.
    Kontoghiorghes GJ; Agarwal MB; Tondury P; Kersten MJ; Jaeger M; Vreugdenhil G; Vania A; Rahman YE
    Lancet; 1993 Jun; 341(8858):1479-80. PubMed ID: 8099176
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of oral iron chelator L1 on iron absorption in man.
    Dresow B; Fischer R; Nielsen P; Gabbe EE; Piga A
    Ann N Y Acad Sci; 1998 Jun; 850():466-8. PubMed ID: 9668586
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients.
    Vreugdenhil G; Swaak AJ; Kontoghiorghes GJ; van Eijk HG
    Lancet; 1989 Dec; 2(8676):1398-9. PubMed ID: 2574342
    [No Abstract]   [Full Text] [Related]  

  • 11. Posterior subcapsular opacity in two patients with thalassaemia major following deferiprone consumption.
    Mehdizadeh M; Nowroozzadeh MH
    Clin Exp Optom; 2009 Jul; 92(4):392-4. PubMed ID: 19515094
    [No Abstract]   [Full Text] [Related]  

  • 12. Deferiprone: second-line treatment of iron overload in the absence of a better alternative.
    Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17926834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral iron chelators.
    Lancet; 1989 Oct; 2(8670):1016-7. PubMed ID: 2572743
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term therapy with deferiprone.
    Olivieri NF
    Acta Haematol; 1996; 95(1):37-48. PubMed ID: 8604585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment with deferiprone in a L1 veteran.
    Meo A; Ruggeri A; La Rosa MA; Zanghì L; Kordes U; Fischer R
    Eur J Haematol; 2005 Jun; 74(6):523-5. PubMed ID: 15876257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deaths in patients receiving oral iron chelator L1.
    Mehta J; Singhal S; Mehta BC
    Br J Haematol; 1993 Oct; 85(2):430-1. PubMed ID: 8280622
    [No Abstract]   [Full Text] [Related]  

  • 17. Future of oral iron chelator deferiprone (L1).
    Mehta J; Singhal S; Mehta BC
    Lancet; 1993 Jun; 341(8858):1480. PubMed ID: 8099177
    [No Abstract]   [Full Text] [Related]  

  • 18. Rarity of systemic lupus erythematosus after oral iron chelator L1.
    Olivieri NF; Koren G; Freedman MH; Roifman C
    Lancet; 1991 Apr; 337(8746):924. PubMed ID: 1673008
    [No Abstract]   [Full Text] [Related]  

  • 19. Future of oral iron chelator deferiprone (L1).
    Pfannkuch F; Bentley P; Schnebli HP
    Lancet; 1993 Jun; 341(8858):1480. PubMed ID: 8099178
    [No Abstract]   [Full Text] [Related]  

  • 20. High doses of deferiprone may be associated with cerebellar syndrome.
    Beau-Salinas F; Guitteny MA; Donadieu J; Jonville-Bera AP; Autret-Leca E
    BMJ; 2009 Jan; 338():a2319. PubMed ID: 19164394
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.